Department of Pharmacology & Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University , Manama, Kingdom of Bahrain.
Department of Cardiology, Salmaniya Medical Complex, Ministry of Health , Manama, Kingdom of Bahrain.
Expert Rev Cardiovasc Ther. 2020 Nov;18(11):835-840. doi: 10.1080/14779072.2020.1814144. Epub 2020 Sep 21.
Warfarin exhibits huge inter-individual variability in therapeutic response. We assessed the extent and the factors affecting inter-individual variability in the anticoagulation control using pre-validated pharmacodynamic indices.
Patients receiving warfarin for at least 6 months were recruited. CHA₂DS₂-VASc, HASBLED, SAMe-TT2R2 scores, warfarin sensitive index (WSI), log-INR variability, and warfarin composite measure (WCM) were assessed. National Institute for Health and Care Excellence (NICE) guideline was adhered for assessing the anticoagulation control using time in therapeutic range (TTR) (TTR < 65%-poor; and TTR ≥ 65%-good). Odds ratio [95% confidence interval] was the effect estimate measure.
Eighty-seven (39.5%) of the patients were poorly anticoagulated. Those with lower HASBLED [OR: 0.3; 0.1, 0.6] and SAMe-TT2R2 scores [OR: 0.2; 0.04, 0.7] and higher CHA₂DS₂-VASc score [OR: 1.8; 1.1, 1.3] predicted good anticoagulation control. Thirty-five (15.9%) patients had high INR variability. Lower TTR, shorter duration of therapy, and higher WSI were observed in patients with high INR variability, and presence of drugs with potential interaction significantly predicted high INR variability.
Significant numbers of our patients on warfarin had poor anticoagulation control and high INR variability. We have identified duration of therapy, CHA₂DS₂-VASc score, and WSI as reliable predictors for anticoagulation control and INR variability.
华法林在治疗反应上存在巨大的个体间差异。我们使用经过验证的药效学指标来评估抗凝控制的个体间差异的程度和影响因素。
招募至少接受华法林治疗 6 个月的患者。评估 CHA₂DS₂-VASc、HASBLED、SAMe-TT2R2 评分、华法林敏感指数(WSI)、INR 变异对数和华法林综合指标(WCM)。采用英国国家卫生与临床优化研究所(NICE)指南,通过治疗范围内时间(TTR)评估抗凝控制(TTR < 65%-差;TTR ≥ 65%-好)。比值比(95%置信区间)是效应估计指标。
87 例(39.5%)患者抗凝效果不佳。HASBLED 评分较低(OR:0.3;0.1,0.6)和 SAMe-TT2R2 评分较低(OR:0.2;0.04,0.7)以及 CHA₂DS₂-VASc 评分较高(OR:1.8;1.1,1.3)的患者预测抗凝控制良好。35 例(15.9%)患者 INR 变异较大。INR 变异较大的患者 TTR 较低、治疗持续时间较短、WSI 较高,且具有潜在相互作用的药物存在显著预测 INR 变异。
我们的许多华法林患者抗凝控制不佳且 INR 变异较大。我们已经确定治疗持续时间、CHA₂DS₂-VASc 评分和 WSI 是抗凝控制和 INR 变异的可靠预测指标。